Please login to the form below

Ono

This page shows the latest Ono news and features for those working in and with pharma, biotech and healthcare.

Ono Pharmaceutical has distribution rights for Forxiga in Japan and will co-promote the drug for the treatment of CKD along with AstraZeneca.

Research charity LifeArc cashes $1.2bn royalty from Keytruda

In March it formed a cancer immunotherapy alliance with CRUK and Ono Pharma, in April it licensed an ion channel drug discovery programme to Daiichi Sankyo, and in early May it
BMS adds another Ono drug to its immuno-oncology portfolio

It will collaborate with Ono in developing the drug in Japan, South Korea and Taiwan. ... Ono’s prostaglandin E2 receptor antagonist programmes offer the potential to develop targeted therapies that counteract the effects of an immunosuppressive tumour
Merck settles PD-1 patent lawsuit with BMS and Ono

The initial payment and royalties will be shared between Ono and BMS with the Japanese firm getting a quarter share and BMS pocketing the remainder. ... BMS and Ono were first to market with their Opdivo (nivolumab) PD-1 inhibitor, claiming approval in
Ono faces steep price cut for Opdivo in Japan

Japan has followed through on plans for an out-of-cycle price cut for Ono Pharmaceuticals' cancer drug Opdivo, lowering it by 50%. ... Ono has said it is considering filing an objection to the decision, on the grounds that the move will disrupt its
Merck decision to drop odanacatib lifts UCB/Amgen

Ono Pharmaceutical was also developing a drug in the class called ONO-5334 but pulled the programme in 2012 without giving reasons for the decision, while Medivir discontinued its MIV 701

More from news
Approximately 7 fully matching, plus 31 partially matching documents found.

Deal Watch March 2017

Clearly on a roll with Japan, X-Chem has also signed a deal with Ono Pharmaceutical covering oncology targets.
Deal Watch January 2017

If the old year goes out like a lion, the New Year will come in like a lamb This month saw BMS/Ono reach an agreement with Merck &Co in their ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).
Deal Watch July 2016

In the second immuno-therapy deal to make the top 20 this month ONO Pharmaceuticals paid $12.5m upfront for the rights to develop Celyad's phase I product, allogeneic ... Acquisition. 325. Celyad/ ONO Pharmaceutical. Allogeneic NKR-2 T-cell immunotherapy.
Pharma deals during July 2014

tremelimumab. Existing partners Bristol-Myers Squibb (BMS) and Ono Pharmaceutical also announced that they will jointly develop and commercialise multiple immunotherapies as single and combination treatments.
Pharma deals during August 2013

Onyx has sole marketing rights with the exception of Japan where it is licensed to Ono Pharmaceutical.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Senior Medical Copywriter - Highly Awarded Advertising Agency: £50,000 - £60,000 yearly

Account Director, Healthcare Marketing Creative Agency, Fixed te...: Highly competitive salary

Account Manager, Healthcare Marketing Creative Agency, Fixed ter...: Highly competitive salary

Account Manager, 6 month contract, Healthcare Brand communicatio...: Highly competitive salary

Home Based Account Manager, Medical Communications, UK, Pharma/M...: Highly competitive salary

No results were found

Add my company

Whitepaper: Closing the gap with compelling healthcare communications: Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers: Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs: It’s not a question of ‘if,’ it’s a question of ‘when.’...

Email:
Password: